Better Mental Health
for More People
We are at a crisis point
in mental health provision.
Mental health and addiction (including alcohol), is the 5th leading cause of illness globally, affecting 20% of the world’s population.
Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.
The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change mental health services and deliver significantly better patient outcomes.
Awakn Life Sciences is a clinical-biotech company researching, developing, and delivering evidenced-based psychedelic medicine to treat Addiction and other mental health conditions.
We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Clinics, and Ecosystems.
We have a dual strategic focus to develop and commercialise psychedelic medicine to treat Addiction and other mental health conditions in a UK and EU chain of medical psychedelic clinics.
Our goals are to be a global leader in psychedelic research to treat Addiction, build the UK and EU’s leading chain of medical psychedelic clinics, and scale our reach through our Licencing and Training Ecosystems.
The leading scientific and medical team in the industry
Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Prof. Matt Johnson, Dr. Michael Mithoefer, and Ann Mithoefer
Global research leaders in psychedelic treatments
Dr. Ben Sessa led the world’s only MDMA and AUD study (BIMA) and Prof. Celia Morgan led the world’s leading Ketamine AUD study (KARE)
Strategic partnerships with two leading UK universities for exclusive access to data and findings from recent clinical trials
Clear IP development pathway
• Clinical trials
• Next generation molecules
Scalable Revenue Streams
• Clinic revenue starting in Q1 2021
• Licensed Methods of Treatment 2022 onwards
Significant first mover advantage in UK and EU
400m people and US$19trn GDP
Our business consists of three related and complementary divisions: Research, Clinics, and Ecosystem.
Our team has led clinical trials and research that have defined the psychedelic medicine industry, including: the Bristol Imperial MDMA for Alcoholism (BIMA) study and the Ketamine for Reduction of Alcoholic Relapse (KARE).
We have a portfolio of clinical research and trials planned and initiated focused on treating addiction.
We utilise the effects of the acute drug state induced by psychedelics alongside a course of psychotherapy to treat a range of mental health issues including Addiction, Anxiety, Depression, and PTSD.
• Bristol Q1 2021
• London & Manchester 2021
• Edinburgh, Brighton, Birmingham 2022
• EU 2023+
Scale our reach through our Licencing and Training Ecosystems.
Scientific Advisory Team
Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry
Dr. Ben Sessa about the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial
Awakn Appoints James Collins as Chief Operating Officer
Awakn Strengthens Scientific Leadership Team
Awakn Appoints PRA to Conduct Phase II Study of MDMA